구조모아 (StructureMoa)항암 chemical structure spider web
방문분석
큐레이션 브리핑
경쟁 포지션: Only approved DLL3-directed therapy after the failure of rovalpituzumab tesirine.
기전. Binds DLL3 on SCLC cells and CD3 on T cells, forcing a cytolytic synapse that kills tumor cells regardless of native TCR specificity.
우선 정리한 핵심 프로그램입니다. 공개 출처가 있는 필드만 표시합니다.
구조화 데이터
DLL3 × CD3
Extensive-stage small cell lung cancer after platinum-based chemotherapy
US, JP
Approved
imdelltra · tarlatamab · Imdelltra · AMG 757 · tarlatamab-dlle
2026-09-10
Data Confidence · High
Development Signal · Established
Half-life extended BiTE (bispecific T-cell engager)
Two single-chain variable fragments against DLL3 and CD3 fused to an Fc domain for extended half-life
DLL3 is expressed on ~85–95% of SCLC tumors but almost absent from normal tissue, which is rare for a solid-tumor engager target.
구조화 데이터
DLL3 is expressed on ~85–95% of SCLC tumors but almost absent from normal tissue, which is rare for a solid-tumor engager target.
Neuroendocrine-to-non-neuroendocrine plasticity with DLL3 loss; T-cell exhaustion.
Half-life extended BiTE (bispecific T-cell engager)
DLL3 × CD3 · DLL3 expression by IHC is not required in the label but tracks with the biology.
CRS and neurologic toxicity management during step-up
Only approved DLL3-directed therapy after the failure of rovalpituzumab tesirine.
ES-SCLC progressing on or after platinum-based chemotherapy
2L+
IV with step-up dosing and inpatient monitoring for early cycles
10 mg q2w after step-up
ORR ~40% at the 10 mg dose in DeLLphi-301
CRS and neurologic toxicity management during step-up
Only approved DLL3-directed therapy after the failure of rovalpituzumab tesirine.
Binds DLL3 on SCLC cells and CD3 on T cells, forcing a cytolytic synapse that kills tumor cells regardless of native TCR specificity.
Polyclonal T-cell activation with transient cytokine release during step-up dosing.
T-cell-mediated lysis of DLL3+ neuroendocrine tumor cells.
DLL3 expression by IHC is not required in the label but tracks with the biology.
Neuroendocrine-to-non-neuroendocrine plasticity with DLL3 loss; T-cell exhaustion.
구조화 데이터
xenograft model
Human, cynomolgus
~11 days (Fc-extended)
Cytokine kinetics, T-cell margination, radiographic response
구조화 데이터
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.
FDA accelerated approval (2L ES-SCLC)
APPROVAL · 2024년 5월
바이오정보모아는 연구·교육용 과학·의약품 개발 정보입니다. 진료, 진단, 치료 지침, 규제 자문이 아닙니다.
분석
큐레이션 브리핑
경쟁 포지션: Only approved DLL3-directed therapy after the failure of rovalpituzumab tesirine.
기전. Binds DLL3 on SCLC cells and CD3 on T cells, forcing a cytolytic synapse that kills tumor cells regardless of native TCR specificity.
우선 정리한 핵심 프로그램입니다. 공개 출처가 있는 필드만 표시합니다.
구조화 데이터
DLL3 × CD3
Extensive-stage small cell lung cancer after platinum-based chemotherapy
US, JP
Approved
imdelltra · tarlatamab · Imdelltra · AMG 757 · tarlatamab-dlle
2026-09-10
Data Confidence · High
Development Signal · Established
Half-life extended BiTE (bispecific T-cell engager)
Two single-chain variable fragments against DLL3 and CD3 fused to an Fc domain for extended half-life
DLL3 is expressed on ~85–95% of SCLC tumors but almost absent from normal tissue, which is rare for a solid-tumor engager target.
구조화 데이터
DLL3 is expressed on ~85–95% of SCLC tumors but almost absent from normal tissue, which is rare for a solid-tumor engager target.
Neuroendocrine-to-non-neuroendocrine plasticity with DLL3 loss; T-cell exhaustion.
Half-life extended BiTE (bispecific T-cell engager)
DLL3 × CD3 · DLL3 expression by IHC is not required in the label but tracks with the biology.
CRS and neurologic toxicity management during step-up
Only approved DLL3-directed therapy after the failure of rovalpituzumab tesirine.
ES-SCLC progressing on or after platinum-based chemotherapy
2L+
IV with step-up dosing and inpatient monitoring for early cycles
10 mg q2w after step-up
ORR ~40% at the 10 mg dose in DeLLphi-301
CRS and neurologic toxicity management during step-up
Only approved DLL3-directed therapy after the failure of rovalpituzumab tesirine.
Binds DLL3 on SCLC cells and CD3 on T cells, forcing a cytolytic synapse that kills tumor cells regardless of native TCR specificity.
Polyclonal T-cell activation with transient cytokine release during step-up dosing.
T-cell-mediated lysis of DLL3+ neuroendocrine tumor cells.
DLL3 expression by IHC is not required in the label but tracks with the biology.
Neuroendocrine-to-non-neuroendocrine plasticity with DLL3 loss; T-cell exhaustion.
구조화 데이터
xenograft model
Human, cynomolgus
~11 days (Fc-extended)
Cytokine kinetics, T-cell margination, radiographic response
구조화 데이터
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.
FDA accelerated approval (2L ES-SCLC)
APPROVAL · 2024년 5월
바이오정보모아는 연구·교육용 과학·의약품 개발 정보입니다. 진료, 진단, 치료 지침, 규제 자문이 아닙니다.